PREDICTIVE NEGATIVE VALUE OF PERSISTENT LOW EPSTEIN-BARR VIRUS VIRAL LOAD AFTER INTESTINAL TRANSPLANTATION IN CHILDREN12
- 1 August 2000
- journal article
- research article
- Published by Wolters Kluwer Health in Transplantation
- Vol. 70 (4) , 593-596
- https://doi.org/10.1097/00007890-200008270-00010
Abstract
The correlation between an elevated Epstein-Barr virus(EBV) viral load in the peripheral blood and the subsequent development of EBV-associated posttransplant lymphoproliferative disease (PTLD) is the basis for strategies using serial measurements of the EBV viral load to guide preemptive therapy (PT). Neither the frequency, duration of monitoring, nor the predictive negative value of viral load monitoring for asymptomatic patients with persistent low or nondetectable viral loads against the development of PTLD has been established. Since April 1994, children undergoing intestinal transplantation (ITx) underwent serial monitoring of the EBV viral load in their peripheral blood using a quantitative competitive EBV polymerase chain reaction assay (PCR). Samples were obtained every 2 weeks for the first 3 months and then every 1–3 months depending on the patients clinical condition. EBV viral loads ≥40 (for patients who were EBV seronegative pre-ITx) and≥200 (for those who were seropositive) genome copies/105 peripheral blood lymphocytes were felt to identify patients at increased risk for PTLD and generally prompted PT. A total of 30 ITx recipients were compliant with our monitoring protocol; 23/30 are alive 6–59 months post-ITx. A total of 12/30 never had a viral load >40 and did not receive PT. In contrast, 18/30 had ≥1 high viral load (≥200); the first high viral load was measured a median of 59 days post-ITx (range 1–440). A late rise (>6 months post-ITx) was seen in only 2/18 children. A total of 0/12 patients with persistently low viral loads received PT and none developed PTLD. In contrast, 5/18 with ≥1 one high viral load (including 2/14 who received and 3/4 who did not receive PT) developed PTLD. All five children with PTLD were EBV seropositive pre-ITx and experienced their first high EBV PCR within the first 3 months after ITx. The predictive negative value of persistently low or nondetectable EBV viral loads was 100% in this study. Patients with nondetectable or low viral loads for the first 6 months after ITx did not develop PTLD regardless of their pretransplant EBV serological status. The frequency of viral load monitoring can be safely decreased for patients whose viral loads remain low for the first 6 months ITx.Keywords
This publication has 13 references indexed in Scilit:
- EPSTEIN-BARR VIRUS-INDUCED POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDERSTransplantation, 1999
- The role of viral load in the diagnosis, management, and possible prevention of Epstein-Barr virus–associated posttransplant lymphoproliferative disease following solid organ transplantationCurrent Opinion in Organ Transplantation, 1999
- PREVENTION AND PREEMPTIVE THERAPY OF POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE IN PEDIATRIC LIVER RECIPIENTS1Transplantation, 1998
- New strategies in the prevention and management of Epstein-Barr virus infection and posttransplant lymphoproliferative disease following solid organ transplantationCurrent Opinion in Organ Transplantation, 1998
- Epstein-Barr Virus Infections in Children After Transplantation of the Small IntestineThe American Journal of Surgical Pathology, 1998
- EPSTEIN-BARR VIRUS DNA IN PERIPHERAL BLOOD LEUKOCYTES OF PATIENTS WITH POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASETransplantation, 1995
- Pretransplantation Assessment of the Risk of Lymphoproliferative DisorderClinical Infectious Diseases, 1995
- Early identification of Epstein‐Barr virus‐associated post‐transplantation lymphoproliferative diseaseBritish Journal of Haematology, 1995
- Expression of Epstein–Barr Virus–Encoded Small RNA (by the EBER-1 Gene) in Liver Specimens from Transplant Recipients with Post-Transplantation Lymphoproliferative DiseaseNew England Journal of Medicine, 1992
- Increased Incidence of Lymphoproliferative Disorder after Immunosuppression with the Monoclonal Antibody OKT3 in Cardiac-Transplant RecipientsNew England Journal of Medicine, 1990